This market research report explain current market for erythropoietin drugs in terms of value. The report also highlights the major drivers and challenges, including their profiles related to erythropoietin drugs.
The global market for erythropoietin drugs has been growing at a CAGR (2015 to 2020) of 1.0% driven by the increasing cases of anemia particularly in kidney diseases and cancer globally.
The global market for erythropoietin drugs is expected to grow from $7.0 billion in 2014 to $7.4 billion in 2015 at a year-on-year (YOY) growth rate of 5.1%. In addition, the market is expected to grow at a five-year CAGR (2015 to 2020) of 1.0%, to reach $7.8 billion in 2020.
The major players in the biologic erythropoietin drug market are, Amgen, Inc., Johnson & Johnson and Hoffmann-LA Roche. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer, Inc.), Biocon, Biosidus, 3SBio, are some of the major biosimilar players across regions.